Preliminary evaluation of a new psychotropic drug, lenperone, in the treatment of acute schizophrenia.
An open trial of a new psychotropic drug, lenperone, was carried out in 10 patients with acute schizophrenia. The duration of treatment was 28 days and the maximum dose administered was 60 mg per day. A pronounced antipsychotic effect was seen in half of the patients, although all 10 patients showed a pharmacological response to the drug. The incidence of side-effects was low. Haematological, biochemical and electrocardiographic tests failed to demonstrate any abnormality due to treatment.
D000208:Acute Disease; D000328:Adult; D002090:Butyrophenones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000188:drug therapy*
D002090:Butyrophenones